Ebola Facts

Symptoms, Diagnosis, Treatments,

Protection, Preparedness

Updated 10/21/14
 Symptoms of Ebola
Initial symptoms are nonspecific - may include fever, chills, myalgias, and malaise.
Patients can progress to develop gastrointestinal symptoms:
severe watery diarrhea, nausea, vomiting, abdominal pain
Other symptoms:
chest pain, shortness of breath, headache or confusion, conjunctival injection, hiccups, seizures,
and cerebral edema
Bleeding not universally present but can manifest later as petechiae, ecchymosis/
bruising, or oozing. Frank hemorrhage less common.
Some develop diffuse erythematous maculopapular rash that can desquamate.
Most common symptoms reported during current outbreak:
fever (87%)
fatigue (76%)
vomiting (68%)
diarrhea (66%)
loss of appetite (65%)
Patients with fatal disease develop more severe clinical signs early during infection and die
between days 6 - 16 of complications (mean of 7.5 days).
In non-fatal cases, patients may have fever for several days and improve, around day 6.
The case fatality proportion in West Africa is about 71%

Source: Centers for Disease Control and Prevention. http://www.cdc.gov/vhf/ebola/hcp/clinician-information-us-

healthcare-settings.html Accessed Oct. 14, 2014
 Diagnosis of Ebola
Diagnosing Ebola can be difficult at first since early symptoms, such as fever, are
nonspecific to Ebola infection.

However, if a person has the early symptoms and has had contact with Ebola they
should be isolated and public health professionals notified.

Samples from the patient can then be collected and tested to confirm infection.
Timeline of Infection Diagnostic tests available
Antigen-capture enzyme-linked
immunosorbent assay (ELISA) testing
Within a few days after symptoms begin IgM ELISA
Polymerase chain reaction (PCR)
Virus isolation
Later in disease course or after recovery IgM and IgG antibodies
Immunohistochemistry testing
Retrospectively in deceased patients PCR
Virus isolation

Source: Centers for Disease Control and Prevention http://www.cdc.gov/vhf/ebola/diagnosis/index.html Accessed Oct. 14,
2014
Source: http://www.cdc.gov/vhf/ebola/pdf/checklist-
patients-evaluated-us-evd.pdf Accessed Oct. 14, 2014
Clinical Progression of Ebola

Source: Jonathan B. Perlin, MD, PhD and HCA Clinical Excellence Knowledge Center, 2014
 Treatment of Ebola
There are no approved treatments available for EVD.
Clinical management focus - supportive care of complications:
hypovolemia, electrolyte abnormalities, hematologic abnormalities, refractory shock,
hypoxia, hemorrhage, septic shock, multi-organ failure, and DIC.

Recommended care includes:

volume repletion
maintenance of blood pressure (with vasopressors if needed)
maintenance of oxygenation
pain control
nutritional support
treating secondary bacterial infections and pre-existing comorbidities

Among patients from West Africa, large volumes of intravenous fluids have often been required to
correct dehydration due to diarrhea and vomiting.

Several investigational therapeutics for Ebola virus disease are in development. There are no
approved vaccines available for EVD. Several investigational Ebola vaccines are in development,
and Phase I trials are underway for some vaccine candidates.

Source: Centers for Disease Control and Prevention. http://www.cdc.gov/vhf/ebola/hcp/clinician-information-

us-healthcare-settings.html Accessed Oct. 14, 2014
 Clinical Evidence
CARE COMPONENT CLINICAL MANAGEMENT
Disease Research suggests the virus first infects dendritic cells, disabling immune system, and then attacks the
Pathophysiology4 vascular system, causing hemorrhage, hypotension and shock. The virus also affects the liver (impacting
coagulation proteins), the adrenal gland (affecting steroid synthesis for blood pressure stabilization) and
the gastrointestinal tract (diarrhea).
Hemodynamic Hypotension/Shock: Aggressive IV fluid resuscitation resembling the approach to the septic shock patient
Support1,2,5-7 is identified by the CDC as one of three interventions that impact mortality through observation and case
series. Base fluid selection (Lactated Ringers or Normal Saline) on patient electrolyte status. One animal
Hypotension/shock,
study examined supplemental fluid resuscitation of infected, hypotensive rhesus macaques, which resulted
hemorrhage/DIC
in improved renal parameters. Hydrocortisone may be considered to support viral disruption in steroid
synthesis.
Hemorrhage/DIC: Management of hemorrhage is inconsistent in literature. Literature around previous
outbreak transfusion strategies includes various blood products, antifibrinolytics, and clotting factors. One
recent report suggests the use of melatonin to combat endothelial disruption, disseminated intravascular
coagulation (DIC) and multiple organ hemorrhage due to potential benefit, high safety profile, and limited
alternative therapies.
Respiratory Maintain adequate oxygenation (titrate to SpO2 >90%). To protect the airway and/or treat multisystem
Support1,2,8-10 organ failure, standard mechanical ventilation practices should be followed with the addition of HEPA
Oxygen therapy, filtration of airflow gases. Methods of non-invasive ventilation are not ideal due to increased potential for
ventilation
aspiration and infection transmission. Additional measures including placement of ventilated patients in a
negative pressure room, use of video/optical laryngoscopy for intubation, use of rapid sequence intubation
with neuromuscular blockade, and use of a ventilator-patient monitoring system interface to minimize
entry into the patient room should be considered.1-2,6-8

Source: Jonathan B. Perlin, MD, PhD and HCA Management Services, L.P. 2014
 Clinical Evidence
CARE COMPONENT CLINICAL MANAGEMENT
Infection Treat fever with acetaminophen (avoid aspirin and NSAIDs due to antiplatelet activity). Identify any
Support1,2,6,11 additional sources of infection and treat with appropriate empiric antimicrobials. If sepsis develops,
Fever, secondary administer broad-spectrum IV antibiotics within 1 hour and follow Surviving Sepsis Early Goal Directed
infection, malaise,
Therapy (EGDT). Antiviral and antimalarial agents are not efficacious for Zaire Ebola virus. Consider
plasma transfusion,
antivirals passive immunotherapy early in disease course by transfusing whole blood or plasma donated from a
convalescent patient.
Renal/Hepatic Renal: Advanced stage may lead to impaired kidney function, increased creatinine and BUN, and
Support1,2,4,6,12,13 decreased urine output. Renal failure has been reported in fatal cases. Patients may experience
persistent oliguria, hematuria and proteinuria despite IV fluid resuscitation. Reports of peritoneal and
hemodialysis show no consistent correlation on survivability, and transmission risk to healthcare workers
should be considered.
Hepatic: Patients demonstrate impaired liver function, hepatomegaly and elevated liver enzymes
(ALT/AST), but severity is lower than that seen in hepatitis A/B or yellow fever. One study showed AST
was several times higher than ALT in fatal cases.
Pain Treat mild pain with acetaminophen and moderate to severe pain with opioids. Avoid diclofenac,
Management2,14-16 ibuprofen and other NSAIDS due to antiplatelet activity; avoid tramadol due to seizure activity. The
management of pain resembling the approach to a critically ill patient with potential multi-organ failure
should be followed due to high risk of renal and hepatic failure.
Neurologic Monitor the patient for confusion, anxiety and seizures. Treat anxiety and seizures with
Support1,6 benzodiazepines. Avoid the use of other medications that may reduce seizure threshold. Late in the
Anxiety, Confusion, disease progression, monitor neurologic status for increased intracranial pressure and intracranial
Seizures
hemorrhage.
Source: Jonathan B. Perlin, MD, PhD and HCA Management Services, L.P. 2014
 Clinical Evidence
CARE COMPONENT CLINICAL MANAGEMENT
Gastrointestinal Provide rehydration therapy to prevent volume depletion. Correct abnormal electrolytes. Proton pump
Support1,10 inhibitors should be administered for dyspepsia and gastrointestinal bleed prophylaxis. Administer
Nutrition, antiemetics for nausea/vomiting. Monitor for dehydration.
Nausea/Vomiting,
Diarrhea
Survivability2,3 Dependent upon access to basic care and patient immune status. Current West Africa Ebola strain has
reported 70% mortality rate (October 14, 2014).

Recovery2,13 Recovery (weeks to months) is highly dependent on supportive care and immunologic response of patient.
Men can still transmit Ebola virus through semen for up to 3 months so abstinence is encouraged during
this time. Once fully recovered, patients are no longer able to transmit the virus. Development of
antibodies last at least 10 years but it is unknown if this confers lifelong immunity or if infection with other
strains is possible. Acute complications include: generalized weakness, weight loss, headache, sensory
distortion, migratory arthralgias, skin sloughing, alopecia, and persistent anemia. Uveitis and orchitis can
occur weeks after illness, and virus can persist in aqueous humor and semen.
Experimental No experimental vaccines or antiviral medications have been fully tested for safety or efficacy. ZMapp
Therapies2,4 (Mapp Biopharmaceutical, Inc.), is an experimental treatment of three monoclonal antibodies that bind to
viral protein. All available doses have been distributed at this time. Several experimental vaccines and
treatments in animal models show promise.

Source: Jonathan B. Perlin, MD, PhD and HCA Management Services, L.P. 2014
 Revised Guidance on PPE for Health
Care Workers
Updated guidance on PPE to be used and processes for donning and doffing PPE for health
care workers entering a patient room hospitalized with Ebola. Emphasizes the importance
of training, practice, competence, and observation of health care workers in correct
donning and doffing of PPE selected by the facility.

Key principles:
Prior to patient contact, all workers must have repeated training and demonstrated competency in
Ebola-related infection control, and specifically donning/ doffing proper PPE.

While working in PPE no skin should be exposed.

Overall safe care must be overseen by onsite manager at all times, and each step of every PPE
donning/doffing procedure supervised by a trained observer

Ebola is spread through direct contact with blood or body fluids or with contaminated objects. For
all workers, full body coverage PPE is recommended to reduce the risk of self-contamination

To protect workers, facilities must provide onsite management and oversight on safe use of PPE and
implement administrative and environmental controls

Source: Centers for Disease Control and Prevention. This guidance is current as of October 20, 2014 from
http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html. Please see website for complete details.
 Recommended Administrative and
Environmental Controls for Healthcare Facilities
Protecting workers and preventing spread of Ebola requires proper administrative procedures
and safe work practices including :
Implement triage protocols to identify potential patients and institute precautions
Designate site managers overseeing implementation of safety precautions:
Site managers monitor supply and evaluate care in isolation area
At least one site manager always on-site where Ebola patient is being treated
Identify ahead of time critical care functions and essential workers:
For Ebola patient care
For collection of laboratory specimens
For environmental management and waste
Ensure workers are trained in all recommended protocols and PPE
Workers should practice donning/doffing procedures and demonstrate competency during
training before caring for patients
Use trained observers to monitor correct PPE use and protocol adherence and guide
workers using a checklist for every donning /doffing procedure
Document observer and worker training in donning/doffing and performing necessary
care-related duties while wearing PPE
Designate spaces so that PPE can be donned and doffed in separate areas

Source: Centers for Disease Control and Prevention. This guidance is current as of October 20, 2014 from
http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html. Please see website for complete details.
 Recommended Administrative and
Environmental Controls for Healthcare Facilities
Key safe work practices include:
Isolate patient in room with closed door and private bathroom as soon as possible.
Limit contact with patient and restrict non-essential personnel and visitors.
Monitor patient care area and log entry and exit of all workers
Ensure trained observer watches each donning and doffing procedure and provides
supervisory assurance
Ensure workers have sufficient time to don and doff PPE correctly
Ensure practical precautions taken during patient care:
keeping hands away from the face
limiting touch of surfaces and body fluids
preventing needlestick and sharps injuries
performing frequent disinfection of gloved hands using an alcohol-based hand rub
Disinfect visibly contaminated PPE, surfaces, or equipment
Perform regular cleaning and disinfection of patient care area surfaces
Performed by nurses or physicians as part of patient care activities to limit workers in room.
Implement worker observation in the patient room, if possible
Establish exposure management plan that addresses decontamination and follow-up of an
affected worker. Training on plan and follow-up should be part of the worker training.
Source: Centers for Disease Control and Prevention. This guidance is current as of October 20, 2014 from
http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html. Please see website for complete details.
 Recommended PPE
Key to all PPE is consistent implementation through repeated training and
practice.
Facility should select and standardize PPE for all essential workers directly
interacting with Ebola patients
Provide written protocol outlining procedures for donning and doffing of PPE,
and review and monitor by trained observer
CDC recommends facilities use a powered air-purifying respirator (PAPR) or an N95
or higher respirator in the event of an unexpected aerosol-generating procedure.
For healthcare workers who spend extended periods in PPE, safety and comfort
are critical. Standardizing attire under PPE (e.g., surgical scrubs or disposable
garments and dedicated washable footwear) facilitates donning and doffing
process and eliminates concerns of contamination of personal clothing.
If facilities elect to use different PPE from what is outlined by CDC (e.g., coveralls
with either an integrated hood or a surgical hood with integrated full face shield),
they must train workers and ensure that donning and doffing procedures are
adjusted and practiced accordingly.

Source: Centers for Disease Control and Prevention. This guidance is current as of October 20, 2014
from http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html. Please see website for complete
details.
 Recommended PPE
PAPR or N95 Respirator
PAPR: A PAPR with a full face shield, helmet, or headpiece. Any reusable helmet or headpiece must be covered with a
single-use (disposable) hood that extends to shoulders and fully covers neck and is compatible with selected PAPR.
A PAPR with a self-contained filter and blower unit integrated inside the helmet is preferred.
A PAPR with external belt-mounted blower unit requires adjustment of the sequence for donning and doffing.
N95 Respirator: Single-use (disposable) N95 respirator in combination with single-use (disposable) surgical hood extending
to shoulders and single-use (disposable) full face shield. If N95 respirators are used instead of PAPRs, careful observation is
required to ensure workers are not inadvertently touching faces under face shield during care.
Single-use (disposable) fluid-resistant or impermeable gown that extends to at least mid-calf or
coverall without integrated hood. Coveralls with or without integrated socks are acceptable.
Consideration should be given to gowns or coveralls with thumb hooks to secure sleeves over
inner glove.
Single-use (disposable) nitrile examination gloves with extended cuffs. Two pairs of gloves should
be worn. At a minimum, outer gloves should have extended cuffs.
Single-use (disposable), fluid-resistant or impermeable boot covers that extend to at least mid-calf
or single-use (disposable) shoe covers. Boot and shoe covers should allow for ease of movement
and not present a slip hazard to the worker.
Single-use (disposable) fluid-resistant or impermeable shoe covers are acceptable only if they will be used in combination
with a coverall with integrated socks.
Single-use (disposable), fluid-resistant or impermeable apron that covers torso to level of mid-calf
should be used if Ebola patients have vomiting or diarrhea. If a PAPR will be worn, consider
selecting an apron that ties behind the neck to facilitate easier removal during the doffing
procedure.
Source: Centers for Disease Control and Prevention. This guidance is current as of October 20, 2014 from
http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html. Please see website for complete details.
 For more detail on PPE
for Health Care Workers,
please visit:
http://www.cdc.gov/vhf/
ebola/hcp/infection-
prevention-and-control-
recommendations.html

Source:
http://www.cdc.gov/vhf/ebola/pdf/ppe-
poster.pdf Accessed Oct. 14, 2014
 External (Non-CDC) Resources on PPE

Emory Healthcare: Ebola Preparedness Protocols

University of Nebraska Medical Center: PPE for Ebola
Mdecins Sans Frontires (Doctors without Borders):
Filovirus Haemorrhagic Fever Guideline, 2008[PDF -
134pages]
World Health Organization (WHO): Infection
prevention and control guidance for care of patients
in health-care settings, with focus on Ebola

Source: Centers for Disease Control and Prevention. Accessed October 20, 2014 from
http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html
 Hospital Preparedness Checklist
Every hospital should ensure that it can detect a patient with Ebola, protect health care
workers, and respond in a coordinated fashion.

Many signs and symptoms of Ebola are non-specific and similar to common diseases.

Transmission can be prevented with appropriate infection control measures.

Checklist highlights key areas for hospital emergency management officers, infection
control practitioners, and clinicians to detect possible Ebola cases, protect employees,
and respond appropriately.

Hospitals should review infection control procedures and incorporate plans for
administrative, environmental, and communication measures, as well as personal
protective equipment (PPE) training and education.

Hospitals should also define the individual work practices that will be required to detect
the introduction of a patient with Ebola, prevent spread, and manage the impact on
patients, the hospital, and staff.

Source: Centers for Disease Control and Prevention;. Accessed October 15, 2014
http://www.cdc.gov/vhf/ebola/pdf/hospital-checklist-ebola-preparedness.pdf
 Hospital Preparedness Checklist
Detect:
Screen patients for symptoms and risk factors for Ebola, including fever of greater than 101.5 degrees
and travel to West Africa (in particular, Guinea, Liberia and Sierra Leone).
Patients meeting criteria should be immediately isolated and tested.
Conduct periodic checks to confirm screening procedures and notification, isolation and personal
protective equipment (PPE) procedures.
Protect:
Use CDC-recommended infection control practices
Review, implement and drill with first-contact personnel, clinicians, ancillary staff, and others as
appropriate on:
Infectious disease procedures and protocols
Triage techniques and Ebola screening questions
Disease identification, testing, specimen collection and transport procedures
Isolation, quarantine and security procedures
Communications and reporting procedures
Cleaning and disinfection procedures
Respond:
All staff should know what to do when encountering a suspected Ebola patient.
Ebola is a nationally notifiable disease and must be reported to public health authorities.
Ensure hospital is in contact with local/state health department to confirm communication strategies.
Review plans and protocols, and exercise/test ability to share relevant health data.

Source: American Hospital Association, adapted from Centers for Disease Control and Prevention
Detailed Hospital Checklist for Ebola Preparedness. http://www.cdc.gov/vhf/ebola/pdf/hospital-
checklist-ebola-preparedness.pdf Accessed October 15, 2014
 Surgical Protocol for Possible or
Confirmed Ebola Cases
Elective surgical procedures should not be performed in cases of suspected or
confirmed Ebola.

In cases where an emergency operation must be performed this protocol should be

implemented to minimize risk to hospital personnel.

The choice of operative approach (open or MIS) should take into consideration
minimizing potential hazards to all members of the OR team.

Although protocols for Personal Protective Equipment (PPE) are in place, there is no
guideline for operating room personnel and surgical providers.

The American College of Surgeons has adapted Centers for Disease Control and
Prevention recommendations to the OR environment.

Source: American College of Surgeons. https://www.facs.org/ebola/surgical-protocol

Updated October 6, 2014. Accessed October 16, 2014
Surgical Protocol - Possible or Confirmed Ebola Cases
Patient Transport and Transfer to OR
Health care providers should wear the following to transport and transfer a patient to OR.
Gloves
Level 3 AAMI fluid resistant gown
eye protection (goggles or face shield)
Facemask

Surgical Checklist
Ebola status discussed in pre- and post-op briefing as integral part of Safe Surgery Checklist
All personnel should be aware of potential risks of exposure

OR Staff Personal Protection Equipment

Due to significant risk of exposure all OR room personnel should wear:
Personal Protective Gear
AAMI Level 4* Impervious Surgical Gowns
Leg coverings with full plastic film coating over fabric not just over foot area
Full face shield
Mask
Double gloves
Surgical hood
*Level 4 AAMI rated gowns, drapes, and protective apparel demonstrate the ability to resist
liquid and viral penetration in a laboratory test, ASTM F1671.

Source: American College of Surgeons. https://www.facs.org/ebola/surgical-protocol,

Updated Oct. 6, 2014. Accessed October 16, 2014
Surgical Protocol - Possible or Confirmed Ebola Cases
Surgical Drapes
AAMI Level 4* drapes should be used

Instrumentation and Sharps

Keep sharps to a minimum
Use instruments, rather than fingers, to grasp needles, retract tissue, and
load/unload needles and scalpels
Give a verbal announcement when passing sharps
Avoid hand-to-hand passage of sharp instruments by using a basin or neutral zone
that has been agreed upon at the case start
Use alternative cutting methods such as blunt electrocautery
Substitute endoscopic surgery for open surgery when possible
Use round-tipped scalpel blades instead of pointed sharp-tipped blades
Use elctrocautery preferentially to scalpel for incisions
No needles or sharps on the Mayo stand
No recapping of needles
Use blunt tip suture needles when possible
Continue sharps safety techniques during OR table clean up post-procedure

Source: American College of Surgeons. https://www.facs.org/ebola/surgical-protocol,

Updated Oct. 6, 2014. Accessed October 16, 2014
Surgical Protocol - Possible or Confirmed Ebola Cases
6. OR Staff Exposure
Persons with percutaneous or mucocutaneous exposures to blood, body fluids, secretions, or
excretions should:
Stop working and immediately wash affected skin surfaces with soap and water
Mucous membranes (e.g., conjunctiva) should be irrigated with copious amounts of
water or eyewash solution
Immediately contact hospital Infectious Disease consultant for post-exposure
evaluation.

---------------------------------------------------------------------------------------------------------------------
References
http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf
http://www.cdc.gov/sharpssafety/resources.html
http://www.cdc.gov/vhf/ebola/hcp/infection-prevention-and-control-
recommendations.html

Source: American College of Surgeons. https://www.facs.org/ebola/surgical-protocol,

Updated Oct. 6, 2014. Accessed October 16, 2014
 References
Baize S. et al. Emergence of Zaire Ebola Virus Disease in Guinea -
Prepminary Report. N Engl J Med. 2014 Apr 16. epub
Feldmann H , Geisbert TW. Ebola Haemorrhagic Fever. Lancet.
2011 Mar 5;377(9768):849-62.
Fowler RA, Fletcher T, Fischer WA, et al. Caring for Critically Ill
Patients with Ebola Virus Disease: Perspectives from West Africa.
Am J Respir Crit Care Med. 2014 Aug 25. Epub
Kortepeter MG, Bausch DG, Bray M. Basic Cpnical and Laboratory
Features of Filoviral Hemorrhagic Fever. J Infect Dis. 2011 Nov;204
Suppl 3:S810-6
WHO Ebola Response Team. Ebola Virus Disease in West Africa
The First 9 Months of the Epidemic and Forward Projections. N Eng
J Med. 2014 Sept 23. Epub

Source: http://www.cdc.gov/vhf/ebola/index.html Accessed Oct. 14, 2014

 REFERENCES AND EVIDENCE CLASSIFICATION
1. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. World Health Organization. World Health
Organization , 2014. April 2014. Level 3
2. Ebola (Ebola Virus Disease). Centers for Disease Control and Prevention website http://www.cdc.gov/vhf/ebola/. Updated October 3, 2014. Accessed October 16,
2014. Level 3
3. WHO finds 70 percent Ebola mortality rate. Aljazeera.com Aljazeera America, 15 Oct 2014. Web. 16 Oct 2014.
4. Ansari AA. Clinical features and pathobiology of Ebolavirus infection J Autoimmun 2014 Sep 23. Doi: 10.1016/j.jaut/2014.09.001. [Epub ahead of print] Level 3
5. Kortepeter MG, Salwer JV, Hensley LE, et al. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis 2011
Nov;204 Suppl 3:S1000-10. Animal study
6. Clark DV, Jahrling PB, Lawler JV. Clinical management of filovirus-infected patients. Viruses. 2012; 4, 1668-1686. Level 3
7. Tan DX, Korkmaz A, Reiter RG, Manchester LC. Ebola virus disease: potential use of melatonin as treatment. J Pineal Res 2014 Sep 27. doi: 10.1111/jpi.12186. [Epub
ahead of print] Level 3
8. Ebola Clinical Care Guidelines: a guide for clinicians in Canada.
http://www.ammi.ca/media/69846/Ebola%20Clinical%20Care%20Guidelines%202%20Sep%202014.pdf. Updated August 29, 2014. Accessed October 16, 2014.
Level 3
9. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. The Lancet. 2011;377(9768):849-62. Level 3
10. Fowler RA, Fletcher T, Fischer WA, 2nd, Lamontagne F, Jacob S, Brett-Major D, et al. Caring for critically ill patients with ebola virus disease. Perspectives from west
Africa. Am J Respir Crit Care Med. 2014;190(7):733-7. Level 3
11. Mupapa K, Massamba M, Kibadi K, Kuvala K, Bwaka, et al. Treatment of ebola hemorrhagic fever with blood transfusion from convalescent patients. J Infect Dis.
1999; 179(Suppl 1):S18-23. Level 2
12. Roddy P, Colebunders R, Jeffs B, et al. Filovirus hemorrhagic fever outbreak case management: a review of current and future treatment options. Infect Disease.
2011; 204: S791-S795. Level 3
13. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. Infect Disease. 2011; 204: S810-S816. Level 3
14. WHO: IMAI District Clinician Manual: Hospital Care for Adolescents and Adults- Guidelines for the Management of Common Illnesses with Limited Resources, 2011.
Available at http://apps.who.int/iris/bitstream/10665/77751/1/9789241548281_Vol1_eng.pdf. Level 3
15. Sprecher A. Filovirus haemorrhagic fever guidelines. Mdecins Sans Frontires Belgium 2013. (in draft) Level 3
16. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care
Med 2013; 41:263. Level 3
See handout for evidence classification.

Source: Jonathan B. Perlin, MD, PhD and HCA Management Services, L.P. 2014